{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:40:30Z","timestamp":1790829630488,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,2,6]],"date-time":"2009-02-06T00:00:00Z","timestamp":1233878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00262-008-0653-8","type":"journal-article","created":{"date-parts":[[2009,2,5]],"date-time":"2009-02-05T15:33:10Z","timestamp":1233847990000},"page":"823-830","source":"Crossref","is-referenced-by-count":195,"title":["Ipilimumab: controversies in its development, utility and autoimmune adverse events"],"prefix":"10.1007","volume":"58","author":[{"given":"Jeffrey","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,6]]},"reference":[{"key":"653_CR1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1101\/sqb.1999.64.303","volume":"64","author":"CA Chambers","year":"1999","unstructured":"Chambers CA, Allison JP (1999) CTLA, the costimulatory molecule that doesn\u2019t: regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 64:303\u2013312","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"653_CR2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565\u2013594","journal-title":"Annu Rev Immunol"},{"key":"653_CR3","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734\u20131736","journal-title":"Science"},{"key":"653_CR4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2004.06.017","volume":"21","author":"T Pentcheva-Hoang","year":"2004","unstructured":"Pentcheva-Hoang T, Egen JG, Wojnoonski K et al (2004) B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21:401\u2013413","journal-title":"Immunity"},{"key":"653_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459\u2013465","journal-title":"J Exp Med"},{"key":"653_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1005752510012","volume":"16","author":"JA Newton Bishop","year":"1997","unstructured":"Newton Bishop JA (1997) Molecular pathology of melanoma. Cancer Metastasis Rev 16:141\u2013154","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"653_CR7","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"S Hodi","year":"2003","unstructured":"Hodi S, Mihm MC, Soiffer RJ et al (2003) Biologic activity of cytotoxic T lymphocyte antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100(8):4712\u20134717","journal-title":"Proc Natl Acad Sci USA"},{"key":"653_CR8","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372\u20138377","journal-title":"Proc Natl Acad Sci USA"},{"key":"653_CR9","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043\u20136053","journal-title":"J Clin Oncol"},{"key":"653_CR10","doi-asserted-by":"crossref","unstructured":"Weber JS, Hersh EM, Yellin M et al (2007) The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. J Clin Oncol suppl 25: abstr 8523","DOI":"10.1200\/jco.2007.25.18_suppl.8523"},{"issue":"36","key":"653_CR11","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","volume":"26","author":"J Weber","year":"2008","unstructured":"Weber J, O\u2019Day S, Urba W (2008) Phase I\/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26(36):5950\u20135956","journal-title":"J Clin Oncol"},{"key":"653_CR12","doi-asserted-by":"crossref","unstructured":"Fischkoff SA, Hersh E, Weber J et al (2005) Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol, ASCO annual meeting proceedings 23 June, suppl 1: 7525","DOI":"10.1200\/jco.2005.23.16_suppl.7525"},{"key":"653_CR13","doi-asserted-by":"crossref","unstructured":"Hersh EM, Weber JS, Powderly JD et al (2008) Disease control and long-term survival in chemotherapy-na\u00efve patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine. J Clin Oncol suppl 26: abstr 9022","DOI":"10.1200\/jco.2008.26.15_suppl.9022"},{"key":"653_CR14","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated with CTL-associated 4 blockade. Clin Cancer Res 13:6681\u20136688","journal-title":"Clin Cancer Res"},{"key":"653_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM et al (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455\u2013463","journal-title":"J Immunother"},{"key":"653_CR16","doi-asserted-by":"crossref","unstructured":"Hamid O, Chin K, Li J et al (2008) Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study. J Clin Oncol suppl 26: abstr 9025","DOI":"10.1200\/jco.2008.26.15_suppl.9025"},{"key":"653_CR17","doi-asserted-by":"crossref","unstructured":"Weber JS, Berman D, Siegel J et al (2008) Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol ASCO annual meeting proceedings, Part I, 26 May suppl 20: abstr 9010","DOI":"10.1200\/jco.2008.26.15_suppl.9010"},{"key":"653_CR18","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283\u20132289","journal-title":"J Clin Oncol"},{"key":"653_CR19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","volume":"28","author":"JA Blansfield","year":"2005","unstructured":"Blansfield JA, Beck KA, Tran K et al (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593\u2013598","journal-title":"J Immunother"},{"key":"653_CR20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","volume":"23","author":"K Sanderson","year":"2005","unstructured":"Sanderson K, Scotland R, Lee P et al (2005) Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741\u2013750","journal-title":"J Clin Oncol"},{"key":"653_CR21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864\u2013872","journal-title":"Oncologist"},{"key":"653_CR22","unstructured":"Weber JS, Targan S, Scotland R et al (2006) Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol, ASCO annual meeting proceedings, Part I, 24 June 20, suppl 2510"},{"key":"653_CR23","doi-asserted-by":"crossref","unstructured":"Urba WJ, Weber JS, O\u2019Day SJ et al (2008) Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10\u00a0mg\/kg every 3\u00a0weeks for 4 doses (induction dosing). J Clin Oncol suppl 26: abstr 3018","DOI":"10.1200\/jco.2008.26.15_suppl.3018"},{"key":"653_CR24","doi-asserted-by":"crossref","unstructured":"Hamid O, Urba WJ, Yellin M et al (2007) Kinetics of response to ipilimumab (MDX-010) in patients with stage III\/IV melanoma. J Clin Oncol suppl 25: abstr 8525","DOI":"10.1200\/jco.2007.25.18_suppl.8525"},{"key":"653_CR25","doi-asserted-by":"crossref","unstructured":"Hodi FS, Hoos A, Ibrahim R et al (2008) Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol suppl 26: abstr 3008","DOI":"10.1200\/jco.2008.26.15_suppl.3008"},{"key":"653_CR26","first-page":"1","volume":"8","author":"YM Saenger","year":"2008","unstructured":"Saenger YM, Wolchok JD (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8:1","journal-title":"Cancer Immun"},{"key":"653_CR27","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Ibrahim R, DePril V et al (2008) Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J Clin Oncol suppl 26: abstr 3020","DOI":"10.1200\/jco.2008.26.15_suppl.3020"},{"key":"653_CR28","doi-asserted-by":"crossref","unstructured":"O\u2019Day SJ, Ibrahim R, DePril V et al (2008) Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol suppl 26: abstr 9021","DOI":"10.1200\/jco.2008.26.15_suppl.9021"},{"issue":"8","key":"653_CR29","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105(8):3005\u20133010","journal-title":"Proc Natl Acad Sci USA"},{"key":"653_CR30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1074-7613(00)80406-9","volume":"7","author":"CA Chambers","year":"1997","unstructured":"Chambers CA, Sullivan TJ, Allison JP (1997) Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7:885\u2013895","journal-title":"Immunity"},{"issue":"5899","key":"653_CR31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P et al (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271\u2013275","journal-title":"Science"},{"issue":"11","key":"653_CR32","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","volume":"175","author":"AV Maker","year":"2005","unstructured":"Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175(11):7746\u20137754","journal-title":"J Immunol"},{"issue":"16","key":"653_CR33","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-07-4797","volume":"14","author":"C M\u00e9nard","year":"2008","unstructured":"M\u00e9nard C, Ghiringhelli F, Roux S et al (2008) CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14(16):5242\u20135249","journal-title":"Clin Cancer Res"},{"issue":"39","key":"653_CR34","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","volume":"105","author":"CI Liakou","year":"2008","unstructured":"Liakou CI, Kamat A, Tang DN et al (2008) CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105(39):14987\u201314992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"653_CR35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/CJI.0b013e31817fd8f3","volume":"31","author":"WB Breunis","year":"2008","unstructured":"Breunis WB, Tarazona-Santos E, Chen R et al (2008) Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31(6):586\u2013590","journal-title":"J Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0653-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-008-0653-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0653-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:08:13Z","timestamp":1589540893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-008-0653-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,6]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s00262-008-0653-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,6]]}}}